CASI Pharmaceuticals (CASI) has released an update.
CASI Pharmaceuticals reported a 12% decrease in third-quarter revenue in 2024 compared to the previous year but saw a significant 96% increase from the previous quarter, reaching $7.8 million. The company is making strides in its strategic focus with the approval of a clinical trial in China for a key therapeutic and progress in the U.S. drug application process. However, CASI is facing challenges, including a net loss of $8.4 million and ongoing litigation against former employees.
For further insights into CASI stock, check out TipRanks’ Stock Analysis page.
